Figure 2: TT-10 Activates YAP-TEADs Activity and the Wnt/β-Catenin Signaling Pathway

(A) Transcriptional enhancer factor domain (TEAD) reporter activity in CMs treated with TT-10 and TAZ-12. n = 9 per group. (B) Quantitative imaging assay for YES-associated protein (YAP) nuclear translocation. CMs were treated with TT-10 and TAZ-12 (10 μmol/l). n = 12 (untreated control and TT-10) and 9 (TAZ-12). Scale bar: 50 μm. (C) TCF/LEF reporter activity in CMs treated with TT-10 and TAZ-12. n = 7 per group. (D) Western blot analysis of Wnt/β-catenin signaling pathway-related proteins. CMs were treated with the indicated reagents at the following concentrations for 6 h: TT-10, 10 μmol/l; TAZ-12, 10 μmol/l; (2ʹZ,3ʹE)-6-bromoindirubin-3ʹ-oxime (BIO), 1 μmol/l. n = 6 to 7 per group. (E) Relative expression of Axin2 in CMs treated with TT-10 and BIO for 24 h. n = 7 (untreated), 7 (TT-10), and 4 (BIO). (F) Ratios of EdU-positive CMs 40 h after the treatment with TT-10, TAZ-12, and BIO. n = 3 per group. *p < 0.05, **p < 0.01, and ***p < 0.001 versus the untreated control. #p < 0.05 and ###p < 0.001 versus TT-10. Abbreviations as in Figure 1.